Traffic Lights - Latest Updates

Last updated: 18/02/2020

Other updates on this site
Drug Name Classification Clinical Indication Comments
BOTULINUM NEUROTOXIN TYPE A (Xeomin®) (NEW) Red Chronic sialorrhoea

In line with NICE TA 605

CANNABIDIOL(Epidyolex®) (NEW) Black For use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam

Not yet reviewed

CEFEPIME (Renapime®) (NEW) Black Antibiotic

Not yet reviewed

CEFOXITIN (Renoxitin®) (NEW) Red Antibiotic
DAPAGLIFLOZIN (NEW) Amber Simple With insulin for treating Type 1 diabetes

In line with NICE TA597

Implementation date 28th November 2019

ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (Trikafta®) (NEW) Red Cystic fibrosis as part of managed access programme
ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (NEW) Red In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder

Subject to LPT Managed Entry Requirements

FERRIC MALTOL(Feraccru®) (NEW) Red Iron deficiency anaemia in IBD after at least two failed oral treatment options
GLYCEROL PHENYLBUTYRATE (Ravicti®) (NEW) Black Chronic management of patients with urea cycle disorders (UCDs)

Not yet reviewed

GLYCOPYRRONIUM LIQUID (Colonis) (NEW) Amber Simple Sialorrhoea in paediatrics
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN (CMVIG) (Cytotect CP Biotest®) (NEW) Black Clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy

Not yet reviewed

LEVOFLOXACIN NEBULISER SOLUTION (Quinsair®) (UPDATED) Red Chronic Pseudomonas lung infection in cystic fibrosis (adults)
MEXILETINE (Namuscla®) (NEW) Black Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Not yet reviewed

PARATHYROID HORMONE (Natpar®) (UPDATED) Red Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate.
PATISIRAN (Onpattro®) (NEW) Black Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Not yet reviewed

RIVAROXABAN (Xarelto®) (NEW) Amber Simple Preventing atherothrombotic events in people with coronary or peripheral artery disease

In line with NICE TA607

ROMOSOZUMAB SOLUTION FOR INJECTION (Evenity®) (NEW) Black Severe osteoporosis in postmenopausal women at high risk of fracture

Not yet reviewed


In line with NICE TA599.

Implementation date 4th December 2019.

SOLRIAMFETOL (Sunosi®) (NEW) Black Improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy

Not yet reviewed

TESTOSTERONE GEL (Tostran ®) (UPDATED) Amber Simple Testosterone deficiency in menopausal women (unlicensed)

Tostran brand only. As per NICE NG 23

TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) Red Cystic Fibrosis
UPADACITINIB (RINVOQ®) (NEW) Black Moderate to severe active rheumatoid arthritis, responded inadequately to, or who are intolerant to one or more DMARDs.

Not yet reviewed

VONICOG ALFA (Veyvondi®) (NEW) Black Von Willebrand disease

Not yet reviewed

VORETIGENE NEPARVOVEC (Luxturna®) (NEW) Black Vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations

Not yet reviewed

VSL#3 (NEW) Black Probiotic

New patients only

ZANAMIVIR SOLUTION FOR INFUSION (Dectova®) (NEW) Red Treatment of complicated and potentially life-threatening influenza

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more